Leelatian N, Sinnaeve J, Mistry A, Barone S, Brockman A, Diggins K, et al. Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells. elife. 2020;9: pubmed publisher

Mahameed M, Boukeileh S, Obiedat A, Darawshi O, Dipta P, Rimon A, et al. Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nat Commun. 2020;11:1304 pubmed publisher

Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9:1683345 pubmed publisher

Zhang Z, Le K, La Placa D, Armstrong B, Miller M, Shively J. CXCR2 specific endocytosis of immunomodulatory peptide LL-37 in human monocytes and formation of LL-37 positive large vesicles in differentiated monoosteophils. Bone Rep. 2020;12:100237 pubmed publisher

Subham S, Jeppson J, Worcester C, Schatmeyer B, Zhao J, Madan R, et al. EGFR as a potent CAR T target in triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2023;197:57-69 pubmed publisher

Staudte S, Klinghammer K, Jurmeister P, Jank P, Blohmer J, Liebs S, et al. Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers. Cancers (Basel). 2022;14: pubmed publisher

Jayasinghe M, Pirisinu M, Yang Y, Peng B, Pham T, Lee C, et al. Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy. Theranostics. 2022;12:3288-3315 pubmed publisher

Marrocco I, Romaniello D, Vaknin I, Drago García D, Oren R, Uribe M, et al. Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. EMBO Mol Med. 2021;13:e13144 pubmed publisher

Kitamura Y, Kanaya N, Moleirinho S, Du W, Reinshagen C, Attia N, et al. Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Sci Adv. 2021;7: pubmed publisher

Pham T, Jayasinghe M, Pham T, Yang Y, Wei L, Usman W, et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021;10:e12057 pubmed publisher

Liu H, Paddock M, Wang H, Murphy C, Geck R, Navarro A, et al. The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer. Cancer Discov. 2020;10:1226-1239 pubmed publisher

Xuan Z, Zhao L, Li Z, Song W, Chen J, Chen J, et al. EPS8L3 promotes hepatocellular carcinoma proliferation and metastasis by modulating EGFR dimerization and internalization. Am J Cancer Res. 2020;10:60-77 pubmed

Jiao S, Subudhi S, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019;179:1177-1190.e13 pubmed publisher

Salvany Celades M, van der Zwan A, Benner M, Setrajcic Dragos V, Bougleux Gomes H, Iyer V, et al. Three Types of Functional Regulatory T Cells Control T Cell Responses at the Human Maternal-Fetal Interface. Cell Rep. 2019;27:2537-2547.e5 pubmed publisher

Mahameed M, Wilhelm T, Darawshi O, Obiedat A, Tommy W, Chintha C, et al. The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors. Cell Death Dis. 2019;10:300 pubmed publisher

Leonard B, Brand T, O Keefe R, Lee E, Zeng Y, Kemmer J, et al. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res. 2018;78:4331-4343 pubmed publisher

Arshad N, Cresswell P. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J Biol Chem. 2018;293:9555-9569 pubmed publisher

Assad Kahn S, Costa S, Gholamin S, Nitta R, Dubois L, Fève M, et al. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway. EMBO Mol Med. 2016;8:511-26 pubmed publisher